Megan McNerney, M.D., Ph.D.
Megan received her B.A. at Northwestern University and M.D. and Ph.D. at The University of Chicago. As an Immunology Ph.D. student in the lab of Vinay Kumar, she studied how natural killer cells eliminate tumor cells, and discovered a novel system of natural killer cell inhibition. She completed her postdoctoral work in Kevin White’s laboratory within the Institute of Genomics and Systems Biology at the University of Chicago, where she characterized the genetic abnormalities in high-risk myeloid neoplasms. Megan is board-certified in Clinical Pathology and is an Attending in the Genomic and Molecular Pathology lab, which is applying next-generation sequencing in clinical diagnostics for oncology patients.
Ningfei An, Ph.D.
Ningfei obtained her Bachelor of Science (BSc) degree from the Department of Pharmaceutical Analysis at Shenyang Pharmaceutical University in China and continued in the same institution to fulfill the requirements for her Master’s degree (MSc) in Pharmacology in 2002. In August of 2002, Dr. An was accepted into the doctoral program in the Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, where she worked on understanding the regulatory roles of a newly discovered protein, Frmpd1. At the Medical University of South Carolina, Ningfei's post-doctoral work focused on the role of Pim kinase in hematopoietic stem cell function and T-ALL. She has published 19 manuscripts in leading stem cell and hematology journals. Ningfei is currently developing and characterizing a mouse model of high-risk myeloid neoplasia.
Molly is an M.D./Ph.D. student in Cancer Biology in the NIH Medical Scientist Training Program. Molly received her Bachelor’s degree in Bioengineering from the University of Illinois Urbana-Champaign.
Senior Research Technologist
Saira received a Master of Science degree in Zoology from Government College, and a second Master's degree in Biological Sciences from Southern Illinois University. She has fourteen years of laboratory research experience. Current projects include characterizing CUX1 interacting proteins, identifying CUX1 genomic targets, and developing critical reagents.
Stephanie is a Ph.D. student in the Committee on Immunology at The University of Chicago. She received a B.S. in both Integrative Biology - Honors and Chemistry from the University of Illinois at Urbana Champaign. She completed a REU at Scripps Research Institute before coming to Chicago.
Jeffrey Kurkewich, Ph.D.
Jeff received a B.S. degree in biological sciences from Eastern Illinois University, where he graduated with honors in 2012. He obtained his PhD at the University of Notre Dame, where his project focused on the role of microRNAs in murine hematopoietic cell fate decisions. Jeff completed his PhD in the spring of 2017 with three first author and four co-author primary literature manuscripts. His current research goals are to elucidate the role of the transcription factor CUX1 in higher-order genome architecture, and to assess its role in the biology of human hematopoietic stem cells. Jeff's long term goals are to pursue a career in academia and ultimately contribute to discoveries that benefit patients with hematological disorders.
Marguerite is an undergraduate at The University of Chicago and recipient of the Biological Sciences Collegiate Division Summer Fellowship (2016) and the Katen Scholarship for summer research (2017) . She is currently studying CUX1 interacting proteins and the mechanism of CUX1 transcriptional regulation.
Robert Arthur, Ph.D. - former lab member
Rob worked on deciphering the cis-regulatory architecture of CUX1 transcriptional activity and how transcription factor haploinsufficiency is translated into alternate transcriptional programs. Rob received his B.A. in Biology from the University of Virgina and Ph.D. from The University of Chicago. He is currently an investigative journalist and writer for FiveThirtyEight.